Noel de Miranda
Interests:
1. Development of personalized immunotherapies for CRC patients
Cancer immunotherapy currently constitutes one of the most promising treatment options for cancer patients. We are working on the development of personalized neo-antigen-targeted immunotherapies, by applying next-generation sequencing technologies for the screening of cancer genomes in advanced colorectal cancer patients. This work is supported by the Fight Colorectal Cancer-Michael’s Mission-AACR Fellowship and the Bas Mulder Award 2015 (Alpe d'HuZes/KWF).
2. Discovery of novel immune cell subsets with anti-cancer activity
The diversity of immune cell entitites might be greater than expected. In a publication in 2012 [1] we described an immune cell subset that was specifically encountered in colorectal cancers that had not metastasized. By applying state-of-the-art technologies like mass cytometry and transcriptome sequencing we are working towards the characterization of this immune cell population. The ultimate objective of this endeavour is to develop a innovative immune cell therapy for metastatic cancer patients. This work is funded by the Veni ZonMw program.
3. Genetics of microsatellite-unstable colorectal cancer
Mutations in the TGFBR2 gene, encoding for a type 2 transmembrane kinase receptor required for transducing TGF-β signaling, are found in the majority of mismatch repair deficient colorectal cancers. We have recently discovered that TGFβ signaling remains active in some MSI-H colorectal cancer cells despite the presence of frameshift mutations in the TGFBR2 gene because the mutated gene still expresses a functional protein. In an accompanying editorial, this work was proposed to constitute a new paradigm in cancer genetics. [2, 3]
4. Genetics of familial colorectal cancer
More than one-fourth of colorectal cancers display familial aggregation, while known cancer syndromes only contribute for approximately 6% of all colorectal cancers, which supports a strong role for elusive genetic factors in the etiology of this disease. We are applying next-generation sequencing technologies for discovering novel genetic predisposition factors to colorectal cancer focusing on families with elevated burdens of colorectal cancer and individuals with young-onset colorectal cancer (< 50 years-old).
1. Development of personalized immunotherapies for CRC patients
Cancer immunotherapy currently constitutes one of the most promising treatment options for cancer patients. We are working on the development of personalized neo-antigen-targeted immunotherapies, by applying next-generation sequencing technologies for the screening of cancer genomes in advanced colorectal cancer patients. This work is supported by the Fight Colorectal Cancer-Michael’s Mission-AACR Fellowship and the Bas Mulder Award 2015 (Alpe d'HuZes/KWF).
2. Discovery of novel immune cell subsets with anti-cancer activity
The diversity of immune cell entitites might be greater than expected. In a publication in 2012 [1] we described an immune cell subset that was specifically encountered in colorectal cancers that had not metastasized. By applying state-of-the-art technologies like mass cytometry and transcriptome sequencing we are working towards the characterization of this immune cell population. The ultimate objective of this endeavour is to develop a innovative immune cell therapy for metastatic cancer patients. This work is funded by the Veni ZonMw program.
3. Genetics of microsatellite-unstable colorectal cancer
Mutations in the TGFBR2 gene, encoding for a type 2 transmembrane kinase receptor required for transducing TGF-β signaling, are found in the majority of mismatch repair deficient colorectal cancers. We have recently discovered that TGFβ signaling remains active in some MSI-H colorectal cancer cells despite the presence of frameshift mutations in the TGFBR2 gene because the mutated gene still expresses a functional protein. In an accompanying editorial, this work was proposed to constitute a new paradigm in cancer genetics. [2, 3]
4. Genetics of familial colorectal cancer
More than one-fourth of colorectal cancers display familial aggregation, while known cancer syndromes only contribute for approximately 6% of all colorectal cancers, which supports a strong role for elusive genetic factors in the etiology of this disease. We are applying next-generation sequencing technologies for discovering novel genetic predisposition factors to colorectal cancer focusing on families with elevated burdens of colorectal cancer and individuals with young-onset colorectal cancer (< 50 years-old).
less
Related Authors
Uploads
Papers by Noel de Miranda